B

Bellerophon Therapeutics Inc
OTC:BLPH

Watchlist Manager
Bellerophon Therapeutics Inc
OTC:BLPH
Watchlist
Price: 0.1025 USD Market Closed
Market Cap: 146.8k USD

Net Margin
Bellerophon Therapeutics Inc

-164.1%
Current
-45%
Average
1.7%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-164.1%
=
Net Income
-9.3m
/
Revenue
5.6m

Net Margin Across Competitors

No Stocks Found

Bellerophon Therapeutics Inc
Glance View

Market Cap
146.8k USD
Industry
Health Care

Bellerophon Therapeutics, Inc. focuses on developing products at the intersection of drugs and devices that address significant unmet medical needs in the treatment of cardiopulmonary diseases. The company is headquartered in Warren, New Jersey and currently employs 20 full-time employees. The company went IPO on 2015-02-13. The firm is focused on developing products that address significant unmet medical needs in the treatment of cardiopulmonary diseases. The focus of the Company’s clinical program is the continued development of its nitric oxide therapy for patients with pulmonary hypertension (PH) using its delivery system, INOpulse. The firm has three subsidiaries: Bellerophon BCM LLC, Bellerophon Pulse Technologies LLC and Bellerophon Services, Inc. The Company’s INOpulse program is an extension of the technology used in hospitals to deliver continuous flow inhaled nitric oxide. INOpulse program is built on scientific and technical developed for the therapeutic delivery of inhaled nitric oxide. The company is developing INOpulse for the treatment of patients with fibrotic interstitial lung disease (fILD) at a risk for pulmonary hypertension, which includes PH associated with idiopathic pulmonary fibrosis.

BLPH Intrinsic Value
Not Available
B
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-164.1%
=
Net Income
-9.3m
/
Revenue
5.6m
What is the Net Margin of Bellerophon Therapeutics Inc?

Based on Bellerophon Therapeutics Inc's most recent financial statements, the company has Net Margin of -164.1%.

Back to Top